Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company, has announced that the first patient has been dosed in the clinical study of mavrostobart (PT199) in combination with chemotherapy.
About Mavrostobart (PT199)
Mavrostobart is an anti-CD73 monoclonal antibody with a differentiated mechanism of action, designed to counter the adenosine-mediated immunosuppressive tumour microenvironment (TME).
Key Advantages
- Complete inhibition of enzyme activities from both soluble and membrane-bound CD73, surpassing many existing anti-CD73 antibodies that only offer incomplete inhibition
- No “hook effect” even at higher concentrations, ensuring consistent inhibition
- Addresses limitations of current CD73 inhibitors
- Aims to enhance antitumor immune activation
- Potentially offers a new treatment option for cancer patients
MORNINGSTAR Clinical Trial
The multi-center Phase I/II clinical trial of mavrostobart (ClinicalTrials.gov ID: NCT05431270), named the MORNINGSTAR study, is currently underway.
Study Objectives
- Evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy
- Test mavrostobart alone and in combination with a PD-1 inhibitor or chemotherapy
Global Reach
A Phase I clinical trial of mavrostobart is also being conducted in China (Clinical Trial Registry ID: CTR20242381).
About Phanes Therapeutics
Phanes Therapeutics, Inc. is a clinical-stage biotech company dedicated to innovative drug discovery and development in oncology.
Ongoing Clinical Programs
Phanes is currently conducting three Phase I/II clinical trials, including:
- MORNINGSTAR study with mavrostobart (PT199) – a best-in-class monoclonal antibody (mAb)
- TWINPEAK study with spevatamig (PT886)
SKYBRIDGE study with peluntamig (PT217)
